Navigation Links
UT Southwestern research reveals how cancer-driving enzyme works
Date:5/6/2011

DALLAS May 6, 2011 Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth.

Their latest findings, published today in Molecular Cell, demonstrate that telomerase repairs chromosomes in one of two ways depending on whether a cell is dividing normally or if the cell is under stress from enzyme inhibition and could lead to new or improved cancer-fighting therapies that promote inhibition of this enzyme.

"It's a significant advance in our understanding of how telomerase works," said Dr. Woodring Wright, professor of cell biology and senior author of the study. "Our goal is to identify new targets for inhibiting telomerase."

The number of times a cell divides is determined by telomeres, protective caps on the ends of chromosomes that indicate cell age. Every time a cell divides, the telomeres shorten. When telomeres shrink to a certain length, the cell either dies or stops dividing. In cancer cells, the enzyme telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing.

Although telomerase was discovered in 1985, exactly how this enzyme repairs telomeres to enable cancer cells to divide and grow was largely unknown. Until now, researchers didn't know how many telomerase molecules went into action at the telomeres and under what conditions.

"It's a single molecule under normal cancer growth conditions, but if you shorten telomeres artificially by inhibiting telomerase, now it's more than one molecule acting on the ends of the telomeres," Dr. Wright said of the study's findings.

When acting as a single molecule at the telomeres, telomerase adds about 60 nucleotide molecules "in one fell swoop to the end of the chromosome," Dr. Wright said.

Researchers also discovered that structures in cells called Cajal bodies help process telomerase during chromosome-repair activity. Cajal bodies assemble ribonucleic acid (RNA) within proteins.

"Telomerase uses this RNA in order to add the sequences onto the end, and this complex is assembled or modified in some way in these Cajal bodies," Dr. Wright said.

UT Southwestern scientists next will work to pinpoint the precise molecules that bring telomerase to telomeres for potential development of inhibitors that would be new cancer drugs.

"We now need to find the molecules that are doing that as targets for additional inhibitors," Dr. Wright said. "We have identified the step, but we haven't yet identified the molecules involved."

One drug that blocks telomerase, Imetelstat or GRN163L, was developed by the biotechnology company Geron with help from Drs. Wright and Jerry Shay, professor of cell biology. That drug, tested at UT Southwestern, is currently in clinical trials for treatment of several types of cancer.


'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related biology news :

1. Signaling path in brain may prevent that Im full message, UT Southwestern scientists discover
2. Team of scientists predicts continued death of forests in southwestern US due to climate change
3. UT Southwestern researchers uncover culprits in life-threatening clotting disorder
4. Alcohol consumers are becoming the norm, UT Southwestern analysis finds
5. UT Southwestern researchers find key step in bodys ability to make red blood cells
6. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
7. UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle
8. UT Southwestern researchers identify key molecular step to fighting off viruses
9. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
10. New brain nerve cells key to stress resilience, UT Southwestern researchers find
11. UT Southwestern student receives fellowship from Howard Hughes Medical Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
Breaking Biology Technology: